“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.”
Research in Action
I design and lead quantitative and qualitative initiatives to clarify opportunity, segment demand, and refine positioning. Using business modeling frameworks such as TAM/SAM/SOM, strategy is grounded in validated insight—not assumptions.
My work has spanned product validation and beta initiatives, partnering across clinical, engineering, and commercial teams to ensure evidence directly informs positioning, regulatory readiness, and launch strategy. I collaborate with HCPs, specialists, product managers, and sales leaders to ensure alignment.
Working with modern tools, LEAN, and value-mapping frameworks, I analyze workflows and commercial processes to identify friction, inefficiencies, and adoption barriers. The time spent on discovery ensures that the validated strategy translates into actual improvements.
Innovate & Stay Competitive
Invest in Research, Data Collection, User Studies and Analysis!
How Evidence Translates to Impact
Sharper Strategic Decisions
Identify real market opportunities, assess risk exposure, and prioritize investments based on validated insights rather than internal assumptions.
Clearer Market Positioning
Refine target segments, value propositions, and pricing logic using tested buyer behavior and defensible market data.
Commercial Readiness
Ensure messaging, adoption pathways, and go-to-market assumptions are validated before scaled execution begins.
Operational Clarity
Uncover workflow friction, adoption barriers, and process inefficiencies through structured discovery — connecting product strategy with real-world use.
At Vista Center, a Bay Area non-profit, I reduced costs by 40% across multiple care sites. How? By identifying operational inefficiencies and restructuring workflows. Insights derived from Time and Motion studies. See the example- Giving Back page.
Product validation doesn’t end with internal findings. Insights have the power to strengthen positioning, commercialization, and build market confidence. From lab environments and beta programs to MVP stages, I ensure findings are translated into credible messaging, adoption strategies, and impact. It starts with discovery.
Selected Research / Journals & Publications
I’ve partnered with clinical leaders and frontline operators to translate product validation into published evidence and conference recognition. From neuroradiology to trauma, anesthesia, and pharmacy leadership, these collaborations strengthened credibility, accelerated adoption, and positioned organizations as change makers.
Hospital Pharmacy [Journal of Hospital Pharmacy, 2022] Integration of the Codonics Safe Label System® Anesthesia Workstation into Pediatric Anesthesia Practice: Utilizing Technology to Increase Medication Labeling Compliance and Decrease Medication Discrepancies. [Authors: Children’s Colorado, Patrick Duffy, M.D. et al.]
J Trauma Acute Care Surg [Journal of Trauma Acute Care Surgery, 2019]
Use of ShotSpotter detection technology decreases prehospital time for patients sustaining gunshot wounds [Authors: Anna Goldenberg, D.O, Deviney Rattigan, M.D., Joshua P Hazelton, M.D.]
Hospital Pharmacy [Journal of Hospiital Pharmacy, 2018] Improved Arrangement and Capacity for Medication Transactions: A Pilot Study to Determine the Impact of New Technology on Medication Storage and Accessibility. [Authors: Matthew Kelm, Pharm D., MHA and Udobi Campbell, Pharm D., MBA].
The IMPROVE Study – Poster & Article in ADVANCE for Nurses [2016]. HackensackUMC conducted the IMPact of a Regulated ADC System On Medication Distribution and Administration VariablEs (IMPROVE) study to examine the effects of automation. The study examined 8,000 administered doses of a particular drug and found a 40% reduction in the time to the first dose for patients. [Clinical Leads: Nilesh Desai, Pharm D, and Claudia Douglas, PHD, R.,N., MHA et al.]
The study was supported by Kelly Elliot, a leader in the clinical study space.
Nilesh is also recognized by many healthcare pubs including Fierce Healthcare.
NEJM [New England Journal of Medicine, 2009]
A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures [Authors: David F. Kallmes, M.D., Bryan A. Comstock, M.S., Patrick J. Heagerty, Ph.D., Judith A. Turner, Ph.D., David J. Wilson, F.R.C.R., et al]
JNS [Journal of Neurosurgery, 2009] Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique., [Authors: Peter C. Gerszten, M.D., M.P.H., and Edward A. Monaco III, M.D., Ph.D.
AJNR [American Journal of Neuroradiology, 2007] Plasma-Mediated Radiofrequency Ablation Assisted Percutaneous Cement Injection for Treating Advanced Malignant Vertebral Compression Fractures [Authors: B.A. Georgy, M.D. and W. Wong M.D.]
From collaborating with the late Bassem Georgy, MD [Neuroradiology] to walking the halls of Children's CO Hospital with Patrick Guffey, MD [Anesthesia, CMIO] and at Cooper Health with, Anna Goldenberg, DO [Emergency Med, Trauma] or with Udobi Campbell, Pharm D., and Nilesh Desai, Pharm D. We took our results on the road, presented at leading conferences including NASS, HIMSS and ASHP -strengthening credibility, advancing patient care, positioning organizations as innovators in their field.
I work with organizations to transform their business.
Evidence Based Discovery Framework
Structured quantitative research to validate positioning, pricing, and market adoption- occurs before GTM execution or after to understand buyers.
Structured surveys and measurable research instruments built to test assumptions, quantify demand, and capture defensible market data. Leveraging known survey processes, methodology and instruments.
Positioning, value propositions, and pricing are tested with buyers and advocates to confirm that they resonate, provide product clarity, and adoption potential. Existing market data is compared.
Validated insights are translated into positioning, pricing logic, GTM decisions, and FDA submissions, etc. Executive summaries and actions are delivered to leadership teams.
